Reuters logo
BRIEF-Veloxis Pharmaceuticals - Envarsus receives European Marketing Authorization for treatment of both kidney and liver transplant patients
July 28, 2014 / 6:51 AM / 3 years ago

BRIEF-Veloxis Pharmaceuticals - Envarsus receives European Marketing Authorization for treatment of both kidney and liver transplant patients

July 28 (Reuters) - Veloxis Pharmaceuticals A/S : * Envarsus receives European Marketing Authorization for treatment of both

kidney and liver transplant patients * NDA for Envarsus XR is under regulatory review by FDA and has a PDUFA action

date of October 30, 2014 * Source text for Eikon * Further company coverage

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below